Introgen, Colgate-Palmolive Co. sales and marketing update

The companies partnered to develop and market oral formulations of INGN's mda-7, FUS1 and p53 molecular therapies to prevent oral cancer. CL made a $20 million equity investment in INGN and has the fi...